NEUP
NASDAQ · Biotechnology
Neuphoria Therapeutics Inc
$4.01
+0.02 (+0.38%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 5.17M | 4.87M | 5.69M |
| Net Income | -354,866 | -256,361 | -296,488 |
| EPS | — | — | — |
| Profit Margin | -6.9% | -5.3% | -5.2% |
| Rev Growth | -7.1% | +6.1% | +23.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 5.39M | 4.38M | 5.69M |
| Total Equity | 13.97M | 15.22M | 15.00M |
| D/E Ratio | 0.39 | 0.29 | 0.38 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -507,265 | -425,609 | -470,962 |
| Free Cash Flow | -183,163 | -132,058 | -138,324 |